CAR T-Cell Therapy in Metastatic CRPC and Future Directions in Care
Closing out their final module, expert panelists consider the role of CAR T-cell therapy in metastatic castration-resistant prostate cancer and look toward future evolutions in the broader treatment landscape.
Ongoing Clinical Trials in the Metastatic CRPC Setting
Key opinion leaders in metastatic castration-resistant prostate cancer share insight to key ongoing clinical trials within the landscape.
Potential for CDK4/6 Inhibitors in Metastatic CRPC
Expert panelists briefly reflect on clinical trial data with CDK4/6 inhibitors in metastatic castration-resistant prostate cancer and how their role in this setting might evolve.
Novel Therapeutic Targets in Metastatic CRPC
A broad discussion on emerging therapeutic targets in metastatic castration-resistant prostate cancer and where they may fall within the treatment landscape.
Systemic Treatment Armamentarium in Metastatic HSPC
Shared insight on the range of systemic therapy options available to patients who present with metastatic hormone-sensitive prostate cancer.
Overview of Metastatic HSPC: Diagnosis and Risk Stratification
Opening their first module on metastatic hormone-sensitive prostate cancer, panelists consider optimal diagnostic and risk stratification strategies for when a patient presents in clinic.
Future of Treating mRCC
Treating Patients With mRCC Beyond Second-Line
Strategies for Switching From Frontline Therapy to Second-Line Therapy in mRCC
Clinical Trials Shaping Treatment in Relapsed/Refractory mRCC
Choosing Second-Line Therapy in Treatment of mRCC
Tailored Therapy Approaches for Upfront mRCC Treatment
Treating Side Effects of Therapy for mRCC with Steroids
Evaluating Safety Profiles of Upfront Regimens for mRCC
Choosing Upfront Therapy for mRCC
CheckMate 9ER: Phase 3 Trial of Frontline Nivolumab + Cabozantinib
Evaluating Long-Term Follow-Up Data for Treatment of mRCC
Patient Factor Consideration for Treatment of mRCC
Applying Clinical Trial Data for Treatment of mRCC
Clinical Trials Defining the NCCN Guidelines for Frontline Treatment of mRCC
Evaluation of Risk for Frontline Advanced/Metastatic Clear Cell RCC
Later-Line Ruxolitinib Use Produces Ongoing Benefit in Real-World Patients With cGVHD
Orca-T Data With Survival, Tolerability Extends to Older Patients With Hematologic Cancers
Dr Ramdial on Gemcitabine/Clofarabine/Busulfan for Lymphoma Stem Cell Transplant
Retrospective Analysis Shows Post-HCT Survival Benefits With Orca-T Vs PTCy in Hematologic Malignancies
2 Commerce Drive Cranbury, NJ 08512